Exploring the mechanism of Schisandra rubriflora in the treatment of polycystic ovary syndrome based on network pharmacology and molecular docking

被引:0
|
作者
Dou, Zhengyan [1 ]
Li, Qingxian [2 ]
Zhang, Jing [3 ]
Zhang, Xin [2 ]
机构
[1] Naval Med Univ, Affiliated Hosp 2, Dept Operat Room, Shanghai 200003, Peoples R China
[2] Naval Med Univ, Affiliated Hosp 2, Dept Reprod Med Ctr, Shanghai 200003, Peoples R China
[3] Fudan Univ, Canc Hosp, Dept Integrat Therapy, Shanghai 200000, Peoples R China
关键词
Polycystic ovary syndrome; <italic>S. Rubriflora</italic>; Network pharmacology; Schisandrin; Ovarian granulosa cells; OXIDATIVE STRESS;
D O I
10.1186/s13048-025-01600-x
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
BackgroundPolycystic ovary syndrome (PCOS) is an endocrine disease associated with reproductive and metabolic abnormalities. The aim of this study was to elucidate the effects of Schisandra rubriflora (S. rubriflora) on PCOS and its related mechanisms using network pharmacology, molecular docking and in vitro experiments.Materials and methodsHERB database and SwissTargetPrediction database were used to obtain the active components and the targets of S. rubriflora. Differentially expressed genes (DEGs) associated with PCOS were obtained by analyzing GSE54248 dataset. A protein-protein interaction network was constructed, and topological analyses were performed to identify the hub targets and main bioactive components. The binding abilities between hub targets and key components were studied by molecular docking. Finally, in vitro PCOS models were constructed with KGN cells and rat ovarian granulosa cells, respectively, and the regulatory effects of schisandrin, a key bioactive component of S. rubriflora, on the cells were investigated by in vitro assays.ResultsA total of 14 bioactive ingredients of S. rubriflora and 26 potential therapeutic targets of S. rubriflora in PCOS treatment were obtained. Bioinformatics analyses suggested that the mechanisms of S. rubriflora in treating PCOS were related to IL-17 signaling pathway and TNF signaling pathway. The binding affinities between key components of S. rubriflora (schisandrin, wyerone, and rugosal) and hub targets (PTGS2, MMP9, MCL1, and JUN) were high. Schisandrin could attenuate lipopolysaccharide-induced inflammation, oxidative stress, and apoptosis of KGN cells and rat ovarian granulosa cells, as well as inhibit hub target expression and TNF pathway activation.ConclusionPTGS2, MMP9, MCL1 and JUN are potential targets for S. rubriflora to treat PCOS. Schisandrin, a main component of S. rubriflora, may be a candidate for the treatment of PCOS.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] The mechanism of Leonuri Herba in improving polycystic ovary syndrome was analyzed based on network pharmacology and molecular docking
    Wu, Mali
    Liu, Hua
    Zhang, Jie
    Dai, Fangfang
    Gong, Yiping
    Cheng, Yanxiang
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2023, 26 : 11234
  • [2] Investigation of the Mechanism of Zishen Yutai Pills on Polycystic Ovary Syndrome: A Network Pharmacology and Molecular Docking Approach
    Chen, Yingyin
    Chai, Xinyi
    Zhao, Ying
    Yang, Xinqian
    Zhong, Caiting
    Feng, Yihui
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021
  • [3] The Potential Effect of Rhizoma coptidis on Polycystic Ovary Syndrome Based on Network Pharmacology and Molecular Docking
    Duan, Liyun
    Jin, De
    An, Xuedong
    Zhang, Yuehong
    Zhao, Shenghui
    Zhou, Rongrong
    Duan, Yingying
    Zhang, Yuqing
    Liu, Xinmin
    Lian, Fengmei
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021
  • [4] Network pharmacology and molecular docking study of the active ingredients in Saptasaram kashayam for the treatment of Polycystic ovary syndrome
    Rani, T. Santh
    Lakshmi, P. Premitha Rajya
    Devi, Ch Manga
    INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS, 2023, 60 (02): : 108 - 121
  • [5] Exploring the mechanism of curcumin in the treatment of colon cancer based on network pharmacology and molecular docking
    He, Qingmin
    Liu, Chuan
    Wang, Xiaohan
    Rong, Kang
    Zhu, Mingyang
    Duan, Liying
    Zheng, Pengyuan
    Mi, Yang
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [6] Exploring the mechanism of Suanzaoren decoction in treatment of insomnia based on network pharmacology and molecular docking
    Wang, Shuxiao
    Zhao, Yan
    Hu, Xingang
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [7] Exploring the mechanism of Erchen decoction in the treatment of atherosclerosis based on network pharmacology and molecular docking
    Li, Wenwen
    Zhang, Guowei
    Zhao, Zhenfeng
    Zuo, Yaoyao
    Sun, Zhenhai
    Chen, Shouqiang
    MEDICINE, 2023, 102 (46) : E35248
  • [8] Exploring the mechanism of Tingli Pill in the treatment of HFpEF based on network pharmacology and molecular docking
    Chi, Kuo
    Yang, Saisai
    Zhang, Yao
    Zhao, Yongfa
    Zhao, Jiahe
    Chen, Qiuhan
    Ge, Yuan
    Liu, Jing
    MEDICINE, 2024, 103 (16) : E37727
  • [9] Exploring the Mechanism of Curcumin on Retinoblastoma Based on Network Pharmacology and Molecular Docking
    Wu, Chengfu
    Zheng, Wenli
    Zhang, Jifa
    He, Xingping
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [10] Exploring the mechanism of tenghuang jiangu wan in osteoporosis treatment based on network pharmacology, molecular docking and experimental pharmacology
    Zhang, Wenjing
    Sun, Mingyang
    Lv, Guangfu
    Guo, Wentao
    Hu, Jiannan
    Gu, Jingye
    Wang, Yuchen
    Gong, Qing
    Pi, Zifeng
    Lin, Zhe
    CHINESE JOURNAL OF ANALYTICAL CHEMISTRY, 2024, 52 (01)